iOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer

EQS-News: iOmx Therapeutics AG / Key word(s): Personnel
iOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer

27.06.2024 / 10:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

iOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer

Martinsried / Munich, Germany, June 27, 2024 - iOmx Therapeutics AG (iOmx),
a clinical-stage biopharmaceutical company translating unexplored immune
evasion biology into a growing pipeline of biomarker-enabled drug programs,
today announced the appointment of Florian Schmid as the new Chief Financial
Officer (CFO). Florian will take over responsibilities from Marcus Irsfeld,
who is leaving the company end of June to pursue new opportunities.

"We are thrilled to welcome Florian to the iOmx team. His extensive
experience in financial strategy, international capital markets, and
leadership within the biotech industry will be of immense value as we enter
the next corporate development stage, further advancing our pipeline of
powerful immuno-oncology drug candidates with single agent activity," said
Dr. Apollon Papadimitriou, CEO of iOmx. "We would like to express our
sincere thanks to Marcus for his significant contributions to iOmx' success
over the past years."

Florian Schmid, CFO of iOmx said: "I am honored to join iOmx Therapeutics at
such an exciting time for the company. iOmx has made remarkable strides
translating novel cancer immune biology into clinical and preclinical
programs with highly promising data. I am impressed by the knowledgeable and
successful investor base, as well as the skilled management team that has
consistently reached milestones on time and within budget. I look forward to
contributing to the company's continued success and supporting its mission
to bring innovative treatments to patients in need."

Florian brings over 20 years of experience in financial leadership roles
within the biopharmaceutical, technology and consulting sectors. Prior to
joining iOmx Therapeutics, he served as CFO of Vivoryon Therapeutics.
Previously, he worked as Director of Finance at InflaRx and held various
management positions at Deutsche Telekom. At InflaRx and Vivoryon he
participated in various corporate finance transactions, including a Nasdaq
IPO and follow-on rounds.

Florian earned a degree in business economics from the
Ludwig-Maximilians-University of Munich and started his professional career
at Arthur Andersen and Ernst & Young. He is a Certified Public Accountant
and Certified German Tax Advisor.

About iOmx Therapeutics

iOmx Therapeutics ( www.iomx.com) is a clinical-stage company that harnesses
deep tumor and myeloid biology insights, along with its proprietary iOTargTM
target screening platform, to generate novel treatments for the most
prevalent solid tumor indications. The company is translating unexplored
immune evasion biology into a growing pipeline of biomarker-enabled drug
programs. Focused on developing drugs with single agent activity, iOmx is
creating potential new backbone therapies in a modality-open fashion. By
applying its comprehensive drug discovery & development expertise iOmx is
committed to shaping the future of cancer therapy. The company's lead
program, OMX-0407, is a proprietary first-in-class spectrum-selective SIK
kinase inhibitor and is currently being investigated in Phase I clinical
trials in multiple solid tumors. iOmx is backed by international venture
capital investors, such as Athos Biopharma, Sofinnova Partners, Wellington
Partners, MIG Capital and M Ventures. iOmx is based in Martinsried/Munich,
Germany.

Media contact
MC Services AG
Katja Arnold, Julia von Hummel
T: +49(0)89 2102280
iomx@mc-services.eu


---------------------------------------------------------------------------

27.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

1934037 27.06.2024 CET/CEST